

## Study of Epstein-Barr virus nuclear antigen (*EBNA-1*) variations: V-val type preferentially exists in biopsies of nasopharyngeal carcinoma from Vietnamese patients

Duc Thuan Lao MSc<sup>1,2</sup>, Kim Phuong Truong MSc<sup>2</sup>, Thuy Ai Huyen Le PhD<sup>2,\*</sup>

1. Faculty of Biology and Biotechnology, University of Science, Vietnam National University Ho Chi Minh City, Vietnam

2. Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, Vietnam.

\*Corresponding author: Thuy Ai Huyen Le, PhD, Assoc. Prof, Faculty of Biotechnology, Ho Chi Minh City Open University, Vietnam. Email: thuy.lha@ou.edu.vn.

Received: 03 December 2017

Accepted: 08 February 2018

### Abstract

**Background:** Epstein-barr virus nuclear antigen 1 (*EBNA1*) plays a crucial role in Nasopharyngeal carcinoma (NPC), the most common cancer of head and neck cancer in Asian countries with high incidents. Sequence variations are of high frequency within the functionally important domains of *EBNA-1*, which have been classified into five subtypes: Phenotype (P)-ala, P-thr, V-val, V-leu and V-pro and are related to geographical location. This study aimed to evaluate the variations of *EBNA-1* in NPC biopsy samples from Vietnamese patients.

**Materials and Methods:** In this descriptive analytical study, 20 NPC biopsy samples, which were positively confirmed to NPC, were collected from Cho Ray Hospital. Nested PCR – nucleotide sequencing was applied to analyze the carboxy-terminal region of *EBNA-1*. Phylogenetic analysis was performed using the Molecular Evolutionary Genetics Analysis, version 5.0, by Neighbor-Joining algorithm.

**Results:** The variants of *EBNA-1* have been described based on the amino acid signature at codon 487, including V-val (75.0%), P-ala (10%), P-thr (5%), V-leu (5%). Additionally, the phylogenetic results confirmed that the V-val subtype, detected in this current study of the Vietnamese population, was in accordance with previous studies that V-val is almost an exclusive variation in Asian region, especially with Chinese populations and preferentially exists in biopsies of nasopharyngeal carcinoma.

**Conclusion:** In this initial study, the sub-strains of EBV within V-val subtype of *EBNA-1* was preferential in biopsies of NPC patients. The finding provided the initial data for the potential contribution of *EBNA-1* polymorphisms to etiology of NPC in Vietnamese population.

**Keywords:** Epstein-barr virus, Nasopharyngeal carcinoma, Nuclear antigen, Variations

### Introduction

Nasopharyngeal carcinoma (NPC) is a human malignancy derived from epithelial cells that is a striking geographic, ethnic distribution, but is common in Southern China, Southern Asia (1, 2, 3, 4). Worldwide, the incidence and mortality of NPC were 86,691 cases Age-standardized rate (ASR = 1.2/100,000), and 50,831 cases (ASR = 0.7/100,000), respectively (5, 6). Meanwhile, in Vietnam, the incidence and mortality of NPC were 4,931 cases (ASR = 5.4/100,000) and 2,885 cases (ASR = 3.3/100,000), respectively (5, 6). The major etiological factors proposed for NPC

pathogenesis are significantly associated with Epstein-Barr virus (EBV) infection, genetic susceptibility and environmental factors (7, 8). EBV, also named human herpes virus 4, a member of Herpesviridae family, has been convincingly shown to be associated to human cancers, such as burkitt's lymphoma, nasopharyngeal carcinoma, etc. (7, 9). Among EBV latent genes, Epstein-Barr nuclear antigen 1 (*EBNA-1*) gene, which encodes for EBNA-1 protein, has been proved to be the only latent gene, which expressed in viral-associated tumors and crucial for viral latent infection in DNA replication, transcription and partitioning of viral

genome during cell division by binding to viral latent replication origin regions (10). Up to now, many studies attempted to identify NPC-specific EBV subtypes based on the sequence variation of *EBNA-1* to display a characteristic geographical prevalence and distribution (11, 12, 13, 14). According to the polymorphism at position 487 of *EBNA-1*, EBV has been classified into two prototypes (P) and three variants (V) subtypes, including P-ala, P-thr, V-val, V-leu and V-pro (15- 18). Many studies indicated that V-val was detected almost exclusively in Chinese populations, and preferentially exists in biopsies of NPC (15, 17, 19). Additionally, unlike other EBV-related diseases, EBV with V-val *EBNA-1* subtype has been proven to be frequently associated NPC, and can be especially detected in oral secretion's (17). Hence the further analysis of EBV strains, based on *EBNA-1* sequence variation patterns, is considered as an important approach to understand whether there is a disease-related strain specific or geographic distribution of EBV strains and to establish the early reagents for screening, prediction of nasopharyngeal tumorigenesis.

To our knowledge, up to date, the classification of *EBNA-1* subtypes has not been studied in Vietnamese population. Therefore, in current study, NPC biopsy samples were collected from Vietnamese NPC patients, to exam whether certain *EBNA-1* subtypes are preferentially associated with NPC from distinct geographical location.

## Materials and Methods

In this historical cohort study, all children

### Ethics statement

Institutional Ethics Board approval was obtained from the Medical Ethics Committee of the Cho Ray Hospital, Ho Chi Minh City, Vietnam. The decision number of the permission from Ethical committee: 516/BVCR-HDDD, Cho Ray Hospital, Ho Chi Minh City, Vietnam. All the samples used in this study were agreed

by Cho Ray Hospital and obtained from all participants in this clinical trial.

### Samples collection, DNA isolation

In this descriptive analytical study, 20 NPC tumor biopsies were collected with informed consent from NPC patients, with the age ranged from 30 to 70 years old, mean at  $47.7 \pm 11.38$ , at Cho Ray hospital. All samples were submitted to histopathological department and subsequently proved to have NPC by hematoxylin and eosin examination (Fig. 1). Total of genomic DNA was isolated from biopsies by phenol/chloroform method. Biopsies were lysed in lysis buffer (10 mM Tris-HCl pH = 8, 10 mM EDTA, 150 mM NaCl, 2% SDS) containing Proteinase K (0.1 mg/ml). Then, total of genomic DNA was isolated and purified by using standard phenol-chloroform and ethanol precipitation. The quality and purity of DNA extraction were measured by the evaluation of  $A_{260}/A_{280}$  proportion. Then, the DNA solution was store at EDTA 0.5M, -20°C for PCR assay.

### Nested-polymerase chain reaction assay, phylogenetic analysis

Nested-polymerase chain reaction (Nested-PCR) and direct sequencing were used to detect the sequence of *EBNA-1* gene. The primers of stage 1 (outer primer) and stage 2 PCR (internal primer) were shown in Table 1. Each stage of PCR was performed in a total of 5  $\mu$ l DNA template (in case of stage 1 PCR) or 3  $\mu$ l stage 1 PCR product (in case of stage 2 PCR), 0.75 unit iTaq DNA polymerase (Biorad), 0.5  $\mu$ M each primer, 7.5  $\mu$ l MyTaq™ Mix (Bioline). Thermal cycling was initiated at 95°C for 5 min, followed by 45 cycles of denaturation at 95°C for 30 secs, annealing at the X°C for 30 secs, extension at 72°C for 30secs, and a final extension at 72°C for 10 min (Note: X°C = 55°C (Stage 1) and 58°C (Stage 2). Finally, the PCR products of were separated on 2% agarose gel and visualized by ethidium bromide staining.

The sequencing results of *EBNA-1* were checked by Chromas 2.6.4 (Technelysium) to find out whether there were nucleotide

alterations across amino acid 487 in comparison to the reference sequence of B95-8 prototype (V01555), based on the backbone of the type 1 reference sequence of wild type (NC007605). Alignments between sequences were analyzed using the ClustalW of the Molecular Evolutionary Genetics Analysis (MEGA) software, version 5.0 (20).

For phylogenetic analysis, all isolated sequences were proofread with references to create a homologous database and were subsequently input to MEGA software for multiple alignment and tree reconstruction using NJ algorithm (bootstrap replicate: 1000).

## Results

### Sequence variations data of *EBNA-1* genes

The Nested-PCR products obtained in distinctly different size, yielded a PCR product of 754 bp, as shown in Fig. 2. The amplification of *EBNA-1* fragments was determined by Sanger sequencing, shown in Fig. 3. Based on the amino acid 487, five *EBNA-1* subtypes were detected. Of these subtypes, V-val was predominant (15 of 20 sequences, counting for 75.0%). P-ala, P-thr, V-leu was presented in the remaining sequences. Notably, both V-val, P-thr and P-ala were co-detected (1 of 20 sequences, counting for 10%). Additionally, for each isolate, the sequence of *EBNA-1* gene across amino acid 487 – 595 (nucleotides 97120 – 97236) was compiled and compared with reference sequence (B95-8 prototype, V01555).

As the results, the sequences with identical consensus mutations were arranged into one group, subsequently, four broad patterns of variations were observed (Table 2). The most common pattern: V-val subtype carried 9 consensus sequence changes, including 7 aa changes at residues 487 (Ala → Val), 499 (Asp → Glu), 502 (Leu → Asn), 524 (Thr → Ile), 528 (Ile → Val), 533 (Leu → Ile), 594 (Arg → Lys) and 2 silent changes at 520

(Leu: CTA → CTC), 553 (Pro: CCG → CCA). This consensus sequence is represented by T69 sequence. The common changes of second pattern: P-ala prototype, which is represented by T72 sequence, were characterized by 5 coding changes at residues 499 (Asp → Glu), 502 (Leu → Asn), 524 (Thr → Ile), 588 (Ala → Pro), 594 (Arg → Lys) and 2 silent changes at 520 (Leu: CTA → CTC), 553 (Pro: CCG → CCA). The third pattern: P-thr prototype, represented by T80, carried 8 consensus changes in residues 487 (Ala → Thr), 492 (Ser → Cys), 524 (Thr → Ile), 563 (Met → Ile), 574 (Val → Gly), 585 (Thr → Pro), 594 (Arg → Lys), 595 (Val → Ala) and 3 silent changes at 499 (Asp: GAC → GAT), 520 (Leu: CTA → CTC), 553 (Pro: CCG → CCA). The fourth pattern, represented by T65, was characterized by 9 amino acid changes in residues 487 (Ala → Thr, Val), 492 (Ser → Cys), 502 (Thr → Asn), 524 (Thr → Ile), 574 (Val → Gly), 585 (Thr → Ile), 594 (Arg → Lys) and 3 silent amino changes at 499 (Asp: GAC → GAT), 520 (Leu: CTA → CTC) and 553 (Pro: CCG → CCA).

### Phylogenetic analysis of the *EBNA-1* nucleotide sequences

In order to strengthen the classification of above patterns as true strain, all 20 determined *EBNA-1* sequences in current study and 19 sequences in previous studies, including 5 sequences of V-val subtype, 6 sequences of P-thr subtype, 4 sequences of V-leu, 4 sequences of P-ala subtype (table 3), were enrolled into *EBNA-1* dataset and were used to construct the phylogenetic tree. Additionally, the sequence (NC006146) was used as outgroup in phylogenetic construction. According to the resulting phylogenetic tree conducted on MEGA 5.0 using standard parameters, these isolates were segregated and formed five monophyletic group, just the same as the four variant groups and out group, shown in Fig. 4.

Table I: The primers sequences used in two-stage PCR

Stage	Primer	Sequence (5' – 3')	T <sub>a</sub>
1	EBNA-1-1	TAGTCAGTCATCATCATCCG	55°C
	EBNA-1-2	GGGATTTATTCTTTAGTGCG	
2	EBNA-1-3	GCCATTTTTCCACCCTGTAG	60°C
	EBNA-1-4	ATTGAGGGCGTCTCCTAACA	

Table II: Detail EBNA-1 sequence variations in NPC biopsies

EBNA-1 subtypes	No.	487	492	499	500	502	520	524	528	529
<b>C-terminal</b>		Flanking domain					Core domain			
<b>P-ala</b>	B95.8	GCT	AGT	GAC	GAA	ACT	CTA	ACT	ATT	CCA
		Ala	Ser	Asp	Glu	Thr	Leu	Thr	Ile	Pro
<b>P-ala</b>	T72	...	...	..G	...	..A.	..C	..T.	...	A..
		*	*	Glu	*	Asn	+	Ile	*	Thr
	T96	...	...	..G	...	..A.	..C	..T.	...	...
		*	*	Glu	*	Asn	+	Ile	*	*
<b>P-thr</b>	T80	A..	T..	..T	...	...	..C	..T.	...	...
		Thr	Cys	+	*	*	+	Ile	*	*
<b>V-val</b>	T69	..T.	...	..G	...	..A.	..C	..T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T70	..T.	...	..G	...	..A.	..C	..T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T73	..T.	...	..G	...	..A.	..C	..T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T75	..T.	T..	..G	...	..A.	..C	..T.	G..	...
		Val	Cys	Glu	*	Asn	+	Ile	Val	*
	T77	..T.	...	..G	...	..A.	..C	..T.	...	..A.
		Val	*	Glu	*	Asn	+	Ile	*	Val
	T78	..T.	...	..G	...	..A.	..C	..T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T79	..T.	...	..G	...	..A.	..C	..T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*

	T90	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T91	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T92	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T93	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T94	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T97	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T98	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	Ile	Val	*
	T99	.T.	...	..G	...	.A.	..C	.T.	G..	...
		Val	*	Glu	*	Asn	+	I	Val	*...
<b>V-leu</b>	T76	CT.	T..	..G	..T	.A.	..C	.T.	...	...
		Leu	Cys	Glu	*	Asn	+	Ile	*	*
<b>P-thr/V-val/P-ala</b>	T65	A..	T..	..T	...	.A.	..C	.T.	...	...
		Thr	Cys	+	*	Asn	+	Ile	*	*
		GT.								
		Val								
		G..								
		Ala								
<b>EBNA-1 subtypes</b>	No.	533	553	563	574	585	588	594	595	
<b>C-terminal</b>		<b>Core domain</b>								
<b>P-ala</b>	B95.8	CTT	CCG	ATG	GTT	ACA	GCT	AGG	GTG	
		Leu	Pro	Met	Val	Thr	Ala	Arg	Val	
<b>P-ala</b>	T72	...	..A	...	...	...	C..	.A.	...	

		*	+	*	*	*	Pro	Lys	*
	T96	...	..A	...	...	...	C..	..A.	...
		*	+	*	*	*	Pro	Lys	*
<b>P-thr</b>	T80	...	..A	..T	..G.	C..	...	..A.	..C.
		*	+	Ile	Gly	Pro	*	Lys	Ala
<b>V-val</b>	T69	A..	..A	...	...	..T.	...	..A.	...
		Ile	+	*	*	Ile	*	Lys	*
	T70	A..	..A	...	...	..T.	C..	..A.	...
		Ile	+	*	*	Ile	Pro	Lys	*
	T73	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T75	A..	..A	..T	...	..T.	C..	..A.	...
		Ile	+	Ile	*	Ile	Pro	Lys	*
	T77	...	..A	...	...	..T.	C..	..A.	...
		*	+	*	*	Ile	Pro	Lys	*
	T78	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T79	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T90	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T91	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T92	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T93	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*
	T94	A..	..A	...	...	...	...	..A.	...
		Ile	+	*	*	*	*	Lys	*

	T97	A..	..A	...	...	...	...	.A.	...
		Ile	+	*	*	*	*	Lys	*
	T98	A..	..A	...	...	...	...	.A.	...
		Ile	+	*	*	*	*	Lys	*
	T99	A..	..A	...	...	...	...	.A.	...
		Ile	+	*	*	*	*	Lys	*
<b>V-leu</b>	T76	...	..A	...	.G.	C..	...	.A.	...
		*	+	*	Gly	Pro	*	Lys	*
<b>V-val/P-thr/P-ala</b>	T65	...	..A	...	.G.	.T.	C..	.A.	...
		*	+	*	Gly	Ile	Pro	Lys	*

Note: Numbers across the top correspond to the amino acid positions under which the B95-8 prototype nucleotide sequence and amino acid is listed. In each row, the upper character denotes the nucleotide which differs to the reference sequence, conversely, the dot (.) denotes the same nucleotide to the reference sequence. The below character indicates the amino acid in three letter code which differs to the reference sequence. On the contrary, the \* character indicates the unchanged amino acid, and the + character indicates the unchanged amino acid within the change of the third nucleotide.

Table III: Reference EBNA-1 sequences collected from previous studies

Accession number	Strain	Subtype	Regional distribution
AY961628	GD1	V-val	China
HQ020558	GD2	V-val	China
JQ009376	HKNPC1	V-val	Hong Kong
KC207813	Akata	V-val	Japan
KC617875	C666-1	V-val	Hong Kong
KC207814	Mutu	P-thr	Kenya
U21202	PA	P-thr	England
U21198	LA	P-thr	England
U21205	WW	P-thr	England
U21200	NL	P-thr	England
KC440852	K4123-MiEBV	P-thr	USA
U21196	JF1	V-leu	England
U21201	P3hr1	V-leu	England
KC440851	K4123-Mi	V-leu	USA
DQ279927	AG876	V-leu	Ghana
V01555	B95-8	P-ala	USA
AF192740	P-ala	P-ala	Italia
KT820485	NPC3238	P-ala	Serbia
NC_007605	Wild type	P-ala	-
NC006146	Macacine		Out group

Note: (-): non-remained.






Figure1. Histological examination of (A) undifferentiated carcinoma (WHO type 3); and (B) non-keratinizing squamous cell carcinoma (WHO type 2).




**Figure 2.** Agarose gel electrophoresis of the PCR products of representative NPC biopsy samples. N: negative control; L: 100-bps DNA marker.



**Figure3.** Sequence determination of *EBNA-1* subtypes of representative NPC biopsy samples by Sanger sequencing. (A) Sample T70: V-val subtype; (B) Sample T72: P-ala subtype; (C) Sample T80: P-thr subtype; (D) Sample T76: V-leu subtype; (E) Sample T65: P-thr/V-val/P-ala subtype. The amino codon 487 was indicated in square-symbol. The nucleotide variants are indicated in narrow





**Figure 4.** Phylogenetic tree based on sequences of *EBNA-1* gene by Neighbor-Joining method

## Discussion

The present study presented the initial study of *EBNA-1* sequence variants evaluation on isolates from the NPC endemic area of Vietnam. EBV has been proven to affect most of global population, counting for more than 90%, only a small percentage of infected individuals develop EBV-associated malignancies, originally form the epithelial of the nasopharynx, EBV-associated NPC. *EBNA-1* is consistently presented in all EBV-associated tumors (21). Besides its role in the replication of EBV genome, *EBNA-1* is an important regulator in the transcription of the viral latent genes (21). In addition, *EBNA-1* has been indicated that to be involved in many signaling pathways

related to cell proliferation and apoptosis, such as STAT1 and TGF $\beta$  signaling pathways (21, 22). Geographically-associated polymorphism of *EBNA-1* has been observed in previous studies. The classification of *EBNA-1* subtypes was determined at amino acid 487 into P-ala, P-thr, V-val, V-leu and V-pro subtypes, in which V-val was detected almost exclusively in Chinese populations, Hong Kong (15, 16, 17, 18). In current study, the V-val, P-ala, P-thr and V-leu were observed. Of these subtypes, V-val was the common subtype and preferentially detected (counting for 75.0%) in NPC in Vietnamese population. These findings similar to that of previous studies

demonstrated V-val predominantly exists on Asian population but different from those on Western region (19, 23, 24). Taking together, V-val subtype is the dominant subtype in Asian population.

In present study, we determined the variations in the segment of *EBNA-1* gene across amino acid 487 – 595 (nucleotides 97120 – 97236). Based on the crystal structure analysis, it is divided into two domains, flanking domain (amino acid 461 – 503), which mediated base contacts with DNA binding and core domain (amino acid 504 – 604), which related to the regulation of dimerization, belonged to the C-terminal protein of EBNA-1, based on the background of B95-8 prototype (25, 26). The alteration of amino acid in the flanking domain and core domain of EBNA-1 might affect the ability of DNA binding. In detail, compared to B95-8 prototype, V-val subtype pattern showed 2 aa changes at residues 487, 502 in core domain and 4 aa changes in residues 524, 528, 533, 594 in core domain in C-terminal of EBNA-1. These finding was according to the study of Mai et al (2007) that 4 amino acid mutation fall within the core domain thought to be involved in EBNA-1 dimerization (27). Significantly, the alteration of Ala in B95-8 prototype (P-ala subtype) by Val in the common pattern of V-val subtype (represented by T69 sequence) at codon 487, was also similar to the study Mai et al, 2007, that have been proven to be significant and necessary in initiation of persistent latent infection of EBV in nasopharyngeal cells (27). In Asia, most studies have focused on nasopharyngeal carcinoma, such as Zhang et al (2004) (19) demonstrated that the replacement of threonine by isoleucine at amino acid 524 led to the loss of a phosphorylation in V-val subtype, indicated that V-val subtype infected NPC preferentially led to the susceptibility to a particular EBV isolated in the nasopharynx may exist in NPC development. Thus, taking together, these substitutions of

those amino acid in V-val might have changed the ability of *EBNA-1* to anchor cellular chromosome, to act in replication of viral DNA, and even to facilitate immunological evasion, resulting in easier maintenance of latent infection (15, 19), that contributed to nasopharyngeal carcinogenesis.

According to the result of phylogenetic analysis, all isolates were segregated and formed four monophyletic group, including V-val (Asia), P-ala (non-Asia), P-thr (non-Asia), V-leu (non-Asia), which were similar to the classification based on the four broad patterns of variations. The out group was separated into one monophyletic group to indicate as the role of control for the phylogenetic tree analysis. Based on the result, T69, T70, T73, T75, T77, T78, T79, T90, T91, T92, T93, T94, T97, T98, T99 formed the V-val subtype monophyletic group with the sequence from NPC patients in Asian region: China including AY961628 (GD1) and HQ020558 (GD2), Hong Kong including JQ009376 (HKNPC1), KC617875 (C666-1), Japan KC207813 (Akata). These confirmed that V-val subtype, detected in current study - in Vietnamese population, was according to previous studies that V-val almost exclusively in Asian region - Chinese populations and preferentially exists in biopsies of nasopharyngeal carcinoma (15, 17, 19).

## Conclusion

In conclusion, this study described the subtypes of *EBNA-1* polymorphisms in Vietnamese patients, including V-val, P-ala, P-thr and V-leu, by the nested-PCR sequencing. Of these EBNA-1 subtypes, V-val was the most prevalent *EBNA-1* subtype (counting for 75%) in Vietnamese NPC patients, which were similar to the previous studies demonstrated that V-val preferentially exists in Asia population, such as Hong Kong, China. Our finding provided the initial data for the potential

contribution of *EBNA-1* polymorphisms to etiology of endemic NPC in Vietnamese population. In further study, it is necessary to a larger number and various sources, including non-invasive samples as well as determination of the association V-val subtype with NPC in Vietnamese patients in order to be applied in screening and early prediction of NPC in Vietnamese population.

### Acknowledgements

We wish to express our thanks to the research project sponsored by Ho Chi Minh City Open University. We thank all the recruited participants in this work and Dr. Nguyen Huu Dung, Dr. Nguyen Trong Minh and all the staff members of Otorhinolaryngology in Cho Ray hospital, Ho Chi Minh City, for collecting the samples used in these studies.

### Conflicts of interest

The authors declared that they have no competing interests.

### References

1. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in pre-invasive lesions related to nasopharyngeal carcinoma. *N Engl J Med* 1995;333(11):693-698.
2. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. *Clin Otolaryngol Allied Sci* 2001;26(2):82-92.
3. Da Costa VG, Marques-Silva AC, Moreli ML. The Epstein-Barr virus latent membrane protein-1 (LMP1) 30-bp deletion and XhoI-polymorphism in nasopharyngeal carcinoma: a meta-analysis of observational studies. *Syst Rev* 2015; 13(4):46-49.
4. Dai W, Zheng H, Cheung AK, Lung ML. Genetic and epigenetic landscape of nasopharyngeal carcinoma. *Chin Clin Oncol* 2016;5(2):16-19.
5. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012.
6. Lao TD, Nguyen DH, Nguyen TM, Le T. Molecular Screening for Epstein-Barr virus (EBV): Detection of Genomic EBNA-1, EBNA-2, LMP-1, LMP-2 among Vietnamese Patients with Nasopharyngeal Brush Samples. *Asian Pac J Cancer Prev* 2017;18(6):1675-1679.
7. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. *Cancer Cell* 2004;5(5):423-428.
8. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol* 2014;50(5):330-338.
9. Ko YH. EBV and human cancer. *Exp Mol Med* 2015;47(1):e130-e135.
10. Aiyar A, Tyree C, Sugden B. The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. *EMBO J* 1998;17(21):6394-6403.
11. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. *Virus Res* 2009;143(2):209-221.
12. Mai SJ, Xie D, Huang YF, Wang FW, Liao YJ, Deng HX, et al. The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines. *Oncol Rep* 2010;23(5):1417-1424.
13. Kwok H, Tong AH, Lin CH, Lok S, Farrell PJ, Kwong DL, et al. Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. *PLoS One* 2012;7(5): e36939-e36949.
14. Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. *Chin J Cancer* 2014;33(12):581-590.

15. Snudden DK, Smith PR, Lai D, Ng MH, Griffin BE. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. *Oncogene*1995;10(8):1545-1552.
16. Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, Venkatesh H, et al. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. *Oncogene*1996;13(1):177-181.
17. Gutiérrez MI, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, et al. Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. *J Gen Virol*1997;78(7):1663-1670.
18. Feng FT, Cui C, Liu WS, Guo YM, Feng QS, Chen LZ, et al. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma. *Chin J Cancer* 2015;34:563-572.
19. Zhang XS, Wang HH, Hu LF, Li A, Zhang RH, Mai HQ, et al. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. *Cancer Lett* 2004;211(1):1-18.
20. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 2011;28(10):2731-2739.
21. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. *Rev Med Virol* 2000;10(2):83-100.
22. Wood VH, ONeil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. *Oncogene* 2007;26(28):4135-4147.
23. Sandvej K, Zhou XG, Hamilton-Dutoit S. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. *J Pathol* 2000;191(2):127-131.
24. Wang WY, Chien YC, Jan JS, Chueh CM, Lin JC. Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. *Clin Cancer Res* 2008;8(8):2586-2590.
25. Bochkarev A, Barwell JA, Pfuetzner RA, Bochkareva E, Frappier L, Edwards AM. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. *Cell*1996;84(5):791-800.
26. Ceccarelli DF, Frappier L. Functional Analyses of the EBNA1 Origin DNA Binding Protein of Epstein-Barr Virus. *J Virol* 2000;74(11):4939-4948.
27. Mai SJ, Ooka T, Li DJ, Zeng MS, Jiang RC, Yu XJ, et al. Functional advantage of NPC-related V-val subtype of Epstein-Barr virus nuclear antigen 1 compared with prototype in epithelial cell line. *Oncol Rep*2007; 17(1):141-146.